|
RA patients
|
Controls
| | |
---|
SNP
|
Genotype counts
|
MAF
|
Genotype counts
|
MAF
|
P
|
OR (95% CI)
|
---|
PTPN22 rs2476601
|
1,383/325/35
|
0.11
|
1,405/235/10
|
0.08
|
4.61 × 10−7
|
1.53 (1.29 to 1.8)
|
rs7726839
|
1,012/631/100
|
0.24
|
959/592/88
|
0.23
|
ns
|
1.02 (0.91 to 1.14)
|
rs12573019
|
1,302/405/37
|
0.14
|
1,264/359/27
|
0.13
|
ns
|
1.11 (0.97 to 1.28)
|
rs1168587
|
652/830/260
|
0.39
|
612/762/276
|
0.40
|
ns
|
0.97 (0.87 to 1.05)
|
rs1895535
|
1,602/138/4
|
0.04
|
1,503/137/7
|
0.05
|
ns
|
0.91 (0.72 to 1.15)
|
rs7200573
|
940/687/116
|
0.26
|
890/633/127
|
0.27
|
ns
|
0.97 (0.87 to 1.08)
|
rs11865624
|
1,532/201/10
|
0.06
|
1,424/221/3
|
0.07
|
ns
|
0.92 (0.76 to 1.11)
|
|
Anti-CCP
+
patients
|
Anti-CCP
−
patients
| | |
|
Positive/negative
| |
Positive/negative
| | | |
SE
|
279/174b
| |
116/153b
| |
1.69 × 10−6
|
2.11 (1.56 to 2.88)
|
GSTM1
|
402/376c
|
–
|
186/192c
|
–
|
ns
|
1.10 (0.86 to 1.41)
|
- aComparison of patients with rheumatoid arthritis (RA) and healthy controls for the single-nucleotide polymorphisms (SNPs) from Briggs et al.[22] in the upper rows and comparison between anti–cyclic citrullinated peptide–positive (anti-CCP+) and anti-CPP− RA patients for shared epitope (SE) and glutathione S-transferase Mu 1 (GSTM1) in the lower rows. MAF, Minor allele frequency; ns, Not significant; PTPN22, Protein tyrosine phosphatase nonreceptor type 22. bPositive, SE carrier; negative, SE non-carrier. cPositive, native carrier; negative, null homozygote.